In the competitive Alpha-1 antitrypsin deficiency space, Prime Medicine's strategy is to offer a best-in-class solution. Their prime editing approach permanently corrects the mutation, allowing the body's natural systems ("endogenous control") to regulate the production of fully functional "wild-type" protein, a key differentiator from other therapies.

The key to treating rare diseases is not just CRISPR technology but a regulatory shift toward an "umbrella" or "platform" strategy. This allows multiple drugs for different mutations to be tested under a single trial, drastically lowering costs and making it feasible to develop treatments for tiny patient populations.

EG427 began by focusing narrowly on neurogenic bladder in spinal cord injury patients. This specific application proved the technology's potential, attracted investors, and enabled the company to later expand its pinpoint DNA medicine into a broader platform for neurological diseases.

The highly personalized, N-of-1 approaches developed for rare diseases are not a niche field. With advanced genetic sequencing, it's becoming clear that every disease is effectively rare and unique to the individual. The lessons from rare disease are creating the foundation for all future medicine.

Priovant strategically focuses on rare autoimmune diseases affecting tens of thousands of patients, rather than ultra-rare conditions. This approach addresses significant unmet needs while creating a substantial cumulative market opportunity by aggregating multiple such indications.

While many gene therapies start with rare, fatal diseases to justify risks, Rumagen intentionally targeted large markets like rheumatoid arthritis. Their strategy relies on the fact that pioneers have already established the general safety of gene editing with regulators, opening the door for its application in more common, chronic conditions.

The Innovative Genomics Institute is tackling rare diseases by creating a standardized platform. By keeping elements like the delivery vehicle and enzyme constant and only changing the guide RNA, they aim to create a repeatable 'bucket trial' process for developing hundreds of cures, not just one-offs.

Regeneron pursues therapies for ultra-rare diseases, even without a clear standalone business model. The strategy is to treat these programs as the "tip of the iceberg," establishing a technology platform and biological understanding that can then be expanded to treat much more common diseases.

While leveraging its current liver-focused platform for scalability, Prime Medicine's CEO identifies drug delivery as the key to unlocking future growth. The company is actively scouting for breakthroughs that will allow them to apply their prime editing technology to complex tissues like the brain, muscle, and heart, signaling a critical industry-wide bottleneck.